<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01826474</url>
  </required_header>
  <id_info>
    <org_study_id>PRO045-CLIN-01</org_study_id>
    <nct_id>NCT01826474</nct_id>
  </id_info>
  <brief_title>Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy</brief_title>
  <official_title>A Phase IIb, Open-label Study to Assess the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Multiple Subcutaneous Doses of PRO045 in Subjects With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to see whether PRO045 is safe and effective to use as medication
      for Duchenne Muscular Dystrophy (DMD) patients with a mutation around location 45 in the DNA
      for the dystrophin protein.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase IIb, open-label, multiple-dose study. The study consists of two phases; a dose
      escalation phase (with subsequent dose-titration) and a 48-week treatment phase.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">August 31, 2016</completion_date>
  <primary_completion_date type="Actual">August 31, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in 6 minute walk test</measure>
    <time_frame>after 48 weeks of treatment phase</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle function</measure>
    <time_frame>after 48 weeks of treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>after 48 weeks treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of upper limb</measure>
    <time_frame>after 48 weeks of treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcomes questionnaire</measure>
    <time_frame>after 48 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>after 48 weeks of treatment phase</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>PRO045, cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.15 mg/kg until dose-titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO045, cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg/kg until dose-titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO045, cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0 mg/kg until dose-titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO045, cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6.0 mg/kg until dose-titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO045, cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9.0 mg/kg until move to 48 week treatment phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO045, cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>48 week treatment phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO045, 0.15 mg/kg/week</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>PRO045, cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO045, 1.0 mg/kg/week</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>PRO045, cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO045, 3.0 mg/kg/week</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>PRO045, cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO045, 6.0 mg/kg/week</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>PRO045, cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO045, 9.0 mg/kg/week</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>PRO045, cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO045, selected dose</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>PRO045, cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Duchenne muscular dystrophy resulting from a mutation correctable by treatment with
             PRO045 confirmed by a state-of-the-art DNA diagnostic technique covering all DMD gene
             exons, including but not limited to MLPA (Multiplex Ligation-dependent Probe
             Amplification), CGH (Comparative Genomic Hybridisation), SCAIP (Single Condition
             Amplification/Internal Primer) or HRMCA (High-Resolution Melting Curve Analysis), and
             correctable by PRO045-induced DMD exon 45 skipping in cultured skin-derived
             myo-converted fibroblasts.

          2. Ambulant boys aged at least 5 years on the day of first dosing able to walk for at
             least 230 meters in the 6 minute walking distance (6MWD) test at first screening visit
             and also at the baseline visit. In addition, 2 of the 3 pre-treatment 6MWD tests
             (screen 1, screen 2, baseline) must be within +/-30 metres of each other prior to
             first PRO045 administration.

          3. Adequate quality for biopsy (confirmed with MRI) of the lateral head of the
             gastrocnemius muscle. An alternative muscle may be considered for biopsy but only
             following discussion between the Principal Investigator and the Prosensa Medical
             Monitor.

          4. Life expectancy of at least 3 years after inclusion in the study.

          5. Glucocorticosteroid use which is stable for at least 3 months prior to first PRO045
             administration. Subjects must have been receiving glucocorticosteroids for at least 6
             months prior to the first PRO045 administration.

          6. Willing and able to adhere to the study visit schedule and other protocol
             requirements.

          7. Written informed consent signed (by parent(s)/legal guardian and/or the subject,
             according to the local regulations).

          8. In France, a subject will be eligible for inclusion in this study only if either
             affiliated to, or a beneficiary of, a social security category.

        Exclusion Criteria:

          1. Known presence of dystrophin in â‰¥5% of fibres in a pre-study diagnostic muscle biopsy
             (i.e. historic muscle biopsy taken prior to written informed consent for this study).

          2. Current or history of liver disease or impairment.

          3. Current or history of renal disease or impairment.

          4. At least two aPTT above ULN within the last month.

          5. Screening platelet count below the lower limit of normal (LLN).

          6. Acute illness within 4 weeks prior to first dose of PRO045 which may interfere with
             the study assessments.

          7. Severe mental retardation or behavioural problems which in the opinion of the
             investigator prohibits participation in this study.

          8. Severe cardiomyopathy which in the opinion of the investigator prohibits participation
             in this study. If a subject has a left ventricular ejection fraction &lt;45% at
             screening, the investigator should discuss inclusion of the subject with the Medical
             Monitor.

          9. Expected need for daytime mechanical ventilation within the next year.

         10. Use of anticoagulants, antithrombotics or antiplatelet agents.

         11. Use of idebenone or other forms of coenzyme Q10 within 1 month prior to the start of
             the screening for the study.

         12. Use of nutritional or herbal supplements which, in the opinion of the investigator,
             may influence muscle performance, within 1 month of the study.

         13. Use of any other investigational product or participation in another trial with an
             investigational product, within 6 months prior to the start of the screening for the
             study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>T. Voit, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Myologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Myologie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Genetic Medicine International Centre for Life</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.biomarin.com</url>
    <description>BioMarin website</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2013</study_first_submitted>
  <study_first_submitted_qc>April 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2013</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne muscular dystrophy</keyword>
  <keyword>DMD</keyword>
  <keyword>Prosensa</keyword>
  <keyword>Duchenne</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

